Toripalimab Combined With Chemotherapy and Bevacizumab as First-Line Treatment in Patients With Advanced Cervical Cancer

Phase 2 Unknown 35 enrolled Peking Union Medical College Hospital

NaSingle-groupOpen-labelTreatment

Summary

This is a single-arm, multicenter, phase II study to investigate efficacy and safety of Toripalimab combined with chemotherapy (paclitaxel and cisplatin) and Bevacizumab as first-line treatment in patients with recurrent, refractory and metastatic cervical cancer

Timeline

Start: 2021-08-01
Primary completion: 2022-12-01
Completion: 2023-12-01

Publications

Li C, Liu S, He Y, Yao H, Yuan Z, Yang J, Cao D, Cheng N, Yang J, Peng P, Xiang Y. Toripalimab combined with bevacizumab plus chemotherapy as first-line treatment for refractory recurrent or metastatic cervical cancer: a single-arm, open-label, phase II study (JS001-ISS-CO214). J Gynecol Oncol. 2025 May;36(3):e44. doi: 10.3802/jgo.2025.36.e44. Epub 2024 Oct 25.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Toripalimab	Monoclonal antibody	240 mg	Intravenous
Background	Bevacizumab	Monoclonal antibody	7.5 mg/kg	Intravenous
Background	Cisplatin	Other / unclassified	50 mg/m2	Intravenous
Background	Paclitaxel	Small molecule	175 mg/m2	Intravenous

Toripalimab Combined With Chemotherapy and Bevacizumab as First-Line Treatment in Patients With Advanced Cervical Cancer

Summary

Timeline

Publications

Drugs

Indications